Research programme: diabetic nephropathies therapy - NephroGenex

Drug Profile

Research programme: diabetic nephropathies therapy - NephroGenex

Alternative Names: BST 4946; BST 4996; BST 4997; BST-605

Latest Information Update: 12 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioStratum
  • Developer NephroGenex
  • Class Imidazoles; Piperazines; Pyridines
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 12 May 2006 NephroGenex licenses second generation AGE compounds, including BST 605, from BioStratum
  • 17 Jun 2004 Data presented at the 64th Scientific Sessions of the American Diabetes Association (ADA-2004) have been added to the Diabetes pharmacodynamics section
  • 06 Apr 2004 This programme is available for licensing (http://www.biostratum.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top